151 related articles for article (PubMed ID: 36928564)
1. MRI fat fraction imaging of nodal and bone metastases in prostate cancer.
Qin C; Goldberg O; Kakar G; Wan S; Haroon A; Azam A; Adeleke S
Eur Radiol; 2023 Aug; 33(8):5851-5855. PubMed ID: 36928564
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection.
Brembilla G; Dell'Oglio P; Stabile A; Ambrosi A; Cristel G; Brunetti L; Damascelli A; Freschi M; Esposito A; Briganti A; Montorsi F; Del Maschio A; De Cobelli F
Eur Radiol; 2018 May; 28(5):1969-1976. PubMed ID: 29270644
[TBL] [Abstract][Full Text] [Related]
4. Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease.
Larbi A; Dallaudière B; Pasoglou V; Padhani A; Michoux N; Vande Berg BC; Tombal B; Lecouvet FE
Prostate; 2016 Aug; 76(11):1024-33. PubMed ID: 27197649
[TBL] [Abstract][Full Text] [Related]
5. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
Lecouvet FE; El Mouedden J; Collette L; Coche E; Danse E; Jamar F; Machiels JP; Vande Berg B; Omoumi P; Tombal B
Eur Urol; 2012 Jul; 62(1):68-75. PubMed ID: 22366187
[TBL] [Abstract][Full Text] [Related]
6. Shortening the acquisition time of whole-body MRI: 3D T1 gradient echo Dixon vs fast spin echo for metastatic screening in prostate cancer.
Lecouvet FE; Pasoglou V; Van Nieuwenhove S; Van Haver T; de Broqueville Q; Denolin V; Triqueneaux P; Tombal B; Michoux N
Eur Radiol; 2020 Jun; 30(6):3083-3093. PubMed ID: 32065282
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer.
Freitag MT; Radtke JP; Hadaschik BA; Kopp-Schneider A; Eder M; Kopka K; Haberkorn U; Roethke M; Schlemmer HP; Afshar-Oromieh A
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):70-83. PubMed ID: 26508290
[TBL] [Abstract][Full Text] [Related]
8. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
9. Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer.
Venkitaraman R; Cook GJ; Dearnaley DP; Parker CC; Khoo V; Eeles R; Huddart RA; Horwich A; Sohaib SA
J Med Imaging Radiat Oncol; 2009 Jun; 53(3):241-7. PubMed ID: 19624290
[TBL] [Abstract][Full Text] [Related]
10. Validating the screening criteria for bone metastases in treatment-naïve unfavorable intermediate and high-risk prostate cancer - the prevalence and location of bone- and lymph node metastases.
Rud E; Noor D; Galtung KF; Ottosson F; Jacewicz M; Baco E; Lauritzen PM
Eur Radiol; 2022 Dec; 32(12):8266-8275. PubMed ID: 35939081
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Including Bone in Dixon-Based Attenuation Correction for
Elschot M; Selnæs KM; Johansen H; Krüger-Stokke B; Bertilsson H; Bathen TF
J Nucl Med; 2018 Dec; 59(12):1913-1917. PubMed ID: 29728516
[TBL] [Abstract][Full Text] [Related]
12. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis.
Woo S; Suh CH; Kim SY; Cho JY; Kim SH
Eur Urol; 2018 Jan; 73(1):81-91. PubMed ID: 28412063
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis.
Vargas HA; Schor-Bardach R; Long N; Kirzner AN; Cunningham JD; Goldman DA; Moskowitz CS; Sosa RE; Sala E; Panicek DM; Hricak H
Abdom Radiol (NY); 2017 Jan; 42(1):271-277. PubMed ID: 27480976
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Assessment of Bone Metastasis in Prostate Cancer Using Synthetic Magnetic Resonance Imaging.
Arita Y; Takahara T; Yoshida S; Kwee TC; Yajima S; Ishii C; Ishii R; Okuda S; Jinzaki M; Fujii Y
Invest Radiol; 2019 Oct; 54(10):638-644. PubMed ID: 31192827
[TBL] [Abstract][Full Text] [Related]
16.
Dyrberg E; Hendel HW; Huynh THV; Klausen TW; Løgager VB; Madsen C; Pedersen EM; Pedersen M; Thomsen HS
Eur Radiol; 2019 Mar; 29(3):1221-1230. PubMed ID: 30132104
[TBL] [Abstract][Full Text] [Related]
17. [Detection of bone metastasis of prostate cancer - comparison of whole-body MRI and bone scintigraphy].
Ketelsen D; Röthke M; Aschoff P; Merseburger AS; Lichy MP; Reimold M; Claussen CD; Schlemmer HP
Rofo; 2008 Aug; 180(8):746-52. PubMed ID: 18512192
[TBL] [Abstract][Full Text] [Related]
18.
Hruby G; Eade T; Emmett L; Ho B; Hsiao E; Schembri G; Guo L; Kwong C; Hunter J; Byrne K; Kneebone A
Asia Pac J Clin Oncol; 2018 Aug; 14(4):343-346. PubMed ID: 29663686
[TBL] [Abstract][Full Text] [Related]
19. Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease.
Pasoglou V; Michoux N; Peeters F; Larbi A; Tombal B; Selleslagh T; Omoumi P; Vande Berg BC; Lecouvet FE
Radiology; 2015 Apr; 275(1):155-66. PubMed ID: 25513855
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer.
Harisinghani MG; Barentsz J; Hahn PF; Deserno WM; Tabatabaei S; van de Kaa CH; de la Rosette J; Weissleder R
N Engl J Med; 2003 Jun; 348(25):2491-9. PubMed ID: 12815134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
